Details: pack, label wording, sources, registration
Sangera 100 mg/ml, Solution
10 ml ampoule, solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Off-label intravenous tranexamic acid as an adjunct for selected clinically suspected or documented hyperfibrinolytic bleeding; not routine treatment of every hemorrhage
6.3/10
Situational / acceptable
Details →
vetman assessment
Sangera
×
100 mg/ml, 10 ml ampoule, solution for injection, human medicine
Assessed clinical scope Dog · Off-label intravenous tranexamic acid as an adjunct for selected clinically suspected or documented hyperfibrinolytic bleeding; not routine treatment of every hemorrhage · Intravenous
Care setting Hospital treatment alongside source control, resuscitation and blood-component support, with slow IV administration and thrombotic, renal and neurologic monitoring
vetman score
6.3/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, human · № რ-036510 · Verified on 16 Oct 2026
Off-label use
A situational hospital adjunct when hyperfibrinolysis is suspected or documented. It can suppress fibrinolysis, but has not shown consistent transfusion or survival benefit and must never replace source control, resuscitation or indicated blood components.
Regulatory and scientific credibility 6.0/10
The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.
Clinical efficacy 6.0/10
Canine trials show pharmacodynamic suppression of hyperfibrinolysis, but clinical benefit is inconsistent: hemorrhagic-shock data showed clot effects without transfusion or survival benefit, and small ITP and haemorrhage studies did not establish routine outcome benefit. Use is therefore phenotype-selected and adjunctive.
Safety and tolerability 6.0/10
Short-course canine experience is usable but not benign: vomiting is dose- and rate-sensitive, and thrombosis, hypotension with rapid IV administration, renal accumulation, seizures and rare hypersensitivity require selection and monitoring. These exact human products have no canine target-animal safety dossier.
Clinical practicality 8.0/10
The 100 mg/mL solution permits the sourced 10-15 mg/kg dose as 0.10-0.15 mL/kg with practical syringe accuracy in hospital. The 10 mL presentation requires venous access and slow IV administration but no complex reconstitution.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not use with active intravascular clotting or a current thromboembolic event. An antifibrinolytic can stabilize an unwanted thrombus as well as a haemostatic clot. Tranexamic acid is not a universal haemostatic. Do not delay surgical or procedural source control, resuscitation, diagnostic coagulation assessment or indicated blood-component therapy while giving it. Tranexamic acid is predominantly renally eliminated. Check renal function and hydration and reduce exposure or extend the interval when clearance is impaired; accumulation increases neurologic and thrombotic risk. Use cautiously in patients with a seizure history or neurologic disease. Stop and reassess for myoclonus, twitching, altered mentation or seizures, particularly with high or accumulated exposure. Concurrent prothrombotic products or a strongly hypercoagulable state may add thromboembolic risk. Document the rationale and monitor when combining with coagulation-factor concentrates or other haemostatic drugs. Nausea and vomiting are clinically relevant and can be dose- or administration-rate related; protect the airway in obtunded patients and reassess repeated emesis, aspiration risk or inability to retain oral doses. Stop immediately for suspected hypersensitivity, facial swelling, bronchospasm, collapse or anaphylaxis. A rare canine anaphylactic reaction has been reported and exact human products lack target-animal pharmacovigilance. This presentation is for intravenous use only. Give slowly through verified venous access; rapid IV delivery can cause hypotension, and neuraxial administration is a potentially fatal medication error. Assessment sources +
Close
Cat
Off-label intravenous tranexamic acid as an adjunct for selected clinically suspected or documented hyperfibrinolytic bleeding; not routine treatment of every hemorrhage
5.6/10
Weak evidence support
Details →
vetman assessment
Sangera
×
100 mg/ml, 10 ml ampoule, solution for injection, human medicine
Assessed clinical scope Cat · Off-label intravenous tranexamic acid as an adjunct for selected clinically suspected or documented hyperfibrinolytic bleeding; not routine treatment of every hemorrhage · Intravenous
Care setting Hospital treatment alongside source control, resuscitation and blood-component support, with slow IV administration and thrombotic, renal and neurologic monitoring
vetman score
5.6/10
Weak evidence support
Evidence confidence: Low
Georgia: Yes, human · № რ-036510 · Verified on 16 Oct 2026
Off-label use
A weak, low-confidence feline hospital adjunct. Published use exists, but dosing is non-standardized, outcome evidence is absent and possible adverse events are material; reserve it for an individualized hyperfibrinolytic bleeding rationale with close monitoring.
Regulatory and scientific credibility 6.0/10
The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.
Clinical efficacy 4.5/10
Feline evidence is limited to retrospective clinical use with varied regimens and uncertain causality. A 35-cat multicentre series found no standardized regimen and possible adverse events in 20%; canine mechanistic and outcome studies are indirect and cannot establish feline clinical benefit.
Safety and tolerability 5.0/10
Published feline experience is small and reported possible adverse events in 20%, some severe, although causality was uncertain. Thrombosis, vomiting, hypotension with rapid IV delivery, renal accumulation, seizures and hypersensitivity remain clinically important concerns without a feline target-animal dossier.
Clinical practicality 8.0/10
The 100 mg/mL solution permits the sourced 10-15 mg/kg dose as 0.10-0.15 mL/kg with practical syringe accuracy in hospital. The 10 mL presentation requires venous access and slow IV administration but no complex reconstitution.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not use with active intravascular clotting or a current thromboembolic event. An antifibrinolytic can stabilize an unwanted thrombus as well as a haemostatic clot. Tranexamic acid is not a universal haemostatic. Do not delay surgical or procedural source control, resuscitation, diagnostic coagulation assessment or indicated blood-component therapy while giving it. Tranexamic acid is predominantly renally eliminated. Check renal function and hydration and reduce exposure or extend the interval when clearance is impaired; accumulation increases neurologic and thrombotic risk. Use cautiously in patients with a seizure history or neurologic disease. Stop and reassess for myoclonus, twitching, altered mentation or seizures, particularly with high or accumulated exposure. Concurrent prothrombotic products or a strongly hypercoagulable state may add thromboembolic risk. Document the rationale and monitor when combining with coagulation-factor concentrates or other haemostatic drugs. Nausea and vomiting are clinically relevant and can be dose- or administration-rate related; protect the airway in obtunded patients and reassess repeated emesis, aspiration risk or inability to retain oral doses. Stop immediately for suspected hypersensitivity, facial swelling, bronchospasm, collapse or anaphylaxis. A rare canine anaphylactic reaction has been reported and exact human products lack target-animal pharmacovigilance. This presentation is for intravenous use only. Give slowly through verified venous access; rapid IV delivery can cause hypotension, and neuraxial administration is a potentially fatal medication error. Assessment sources +
Close
Administration route
Intravenous
Registration
Georgia
Yes, human
In force until 27 Sep 2027
Human (Ministry of Health, RAMA)
In the register: სანგერა 100 მგ/მლ, 10 მლ ამპულა, საინექციო ხსნარი
№ რ-036510
Verified on: 16 Oct 2026
EU
No
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
